Amydis, Inc.
San Diego, CA
- UEI
- LCXNBB1KM9K9
- CAGE
- 735B0
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 9310 Athena Cir #100, La Jolla, CA 92037, USA
- Website
- amydis.com
- Founded
- 2013
- Employees
- 1-10
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Adrx, Inc. | Thousand Oaks, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Dzne E.V. | Bonn, NRW | — |
| Bolden Therapeutics Inc. | Providence, RI | — |
| Neurodex Inc. | Natick, MA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| CND Life Sciences, Inc. | Scottsdale, AZ | 621511 Medical Laboratories |
About the company
Amydis, Inc. is a for-profit biotechnology company that provides research and development services focused on novel diagnostics for age-related neurodegenerative diseases. Through federal grants from the National Institutes of Health's National Institute on Aging, Amydis develops and tests fluorescent contrast agents to detect proteinopathies in the retina as a window to pathology in the brain.
Amydis has received four prime federal project grants under the Aging Research program to support the development of retinal diagnostic probes for various protein misfolding disorders. These include a $917,054 grant to generate proof of concept for a fluorescent tracer to detect TDP43 deposits in amyotrophic lateral sclerosis and frontotemporal dementia; an $8,032,937 grant to develop a diagnostic to differentially diagnose Parkinson's disease and related synucleinopathies; a $1,476,636 grant to develop tau retinal tracers for Alzheimer’s disease and other tauopathies; and a $7,658,223 grant to develop an ophthalmic diagnostic probe to detect cerebral amyloid angiopathy. Through these awards, Amydis conducts research and development around manufacturing, formulating, and testing its patented fluorescent contrast agents in animal models and human subjects. The goal is to advance affordable, non-invasive in vivo diagnostics that can detect these diseases at early, presymptomatic stages to enable earlier therapeutic intervention.
Quick answers
Is Amydis, Inc. registered in SAM.gov?
Yes. Amydis, Inc.'s SAM.gov registration is active through December 2, 2026.
What is Amydis, Inc.'s most recent federal award?
Amydis, Inc.'s most recent federal grant award is Development of a topical tracer to detect TDP43 in ALS, late and FTD retinas for AI-powered disease insights… (R44AG078075), from National Institute on Aging (NIH), on August 15, 2022.
On GovTribe
See Amydis, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors